Data files

The cell surface receptor TREM2 is a key genetic risk factor and drug target in Alzheimer’s disease (AD). In the brain, TREM2 is expressed in microglia, where it undergoes proteolytic cleavage, linked to AD risk, but the responsible protease in microglia is unknown. Another microglia-expressed AD risk factor is inactive rhomboid 2 (iRhom2, RHBDF2), which acts as a non-catalytic subunit of the metalloprotease ADAM17. Its function in AD is unknown. To determine whether loss of iRhom2 and ADAM17 ...

The cell surface receptor TREM2 is a key genetic risk factor and drug target in Alzheimer’s disease (AD). In the brain, TREM2 is expressed in microglia, where it undergoes proteolytic cleavage, linked to AD risk, but the responsible protease in microglia is unknown. Another microglia-expressed AD risk factor is inactive rhomboid 2 (iRhom2, RHBDF2), which acts as a non-catalytic subunit of the metalloprotease ADAM17. Its function in AD is unknown. To determine whether loss of iRhom2 and ADAM17 ...

The beta-secretase beta-site APP cleaving enzyme 1 (BACE1) is a major drug target for Alzheimer’s disease (AD). Clinically tested BACE1 inhibitors induced unexpected cognitive side effects that may stem from their cross-inhibition of the homologous protease BACE2. Yet, little is known about BACE2 functions and substrates in vivo and no biomarker is available allowing to monitor the extent of BACE2 inhibition in vivo, in particular in cerebrospinal fluid (CSF). To identify a potential CSF biomarker ...

Quantitative mass spectrometry has transformed proteomics by allowing the simultaneous quantification of thousands of proteins. To boost statistical power, it is necessary to increase sample sizes by combining patient-derived data from various institutions. However, this practice raises significant privacy concerns. We created this dataset comtaining 30 healthy donors and 30 patients suffering from focal segmental glomerulosclerosis - a rare kidney disease - and distributed them to three independent ...

Quantitative mass spectrometry has transformed proteomics by allowing the simultaneous quantification of thousands of proteins. To boost statistical power, it is necessary to increase sample sizes by combining patient-derived data from various institutions. However, this practice raises significant privacy concerns. We created a DIA-LFQ dataset containing 118 samples generated from Escherichia coli MG1655 (DSM 18039) cultures and distributed them to five independent proteomics centers. This ...

The interactome of fibrillar aggregates of the Tau repeat domain fused to YFP (TauRD-Y) was analyzed in HEK293T cells using SILAC. TauRD-Y was immunoprecipitated with anti-GFP antibody from lysates of SILAC-labeled cells expressing TauRD-Y in soluble form (light labeled; L), from cells containing aggregated TauRD-Y in nucleus and cytosol (medium labeled; M), and from cells containing aggregated TauRD-Y mainly localized to the cytoosl (heavy-labeled; H).

The conserved human secreted glycoprotein Clusterin (aka Apolipoprotein-J, ApoJ) is an abundant component of body fluids such as blood plasma and cerebrospinal fluid. Clusterin is thought to function as an extracellular molecular chaperone stabilizing misfolded proteins in solution. In addition, Clusterin forms lipoprotein complexes and fractions with HDL particles in plasma. Variants of the Clusterin gene constitute the third most important genetic risk factor for late-onset Alzheimer's disease. ...